ArticleBMC complementary medicine and therapies2025
Efficacy and safety of Chinese herbal medicine granules plus chemotherapy in patients with EGFR-mutated advanced lung adenocarcinoma post-progression on first-line EGFR-TKI: study protocol for a multicenter, double-blind, randomized controlled trial.
Article in BMC complementary medicine and therapies, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundLung cancer remains one of the leading causes of mortality globally. For patients with epidermal growth factor receptor (EGFR) -mutated lung adenocarcinoma who develop resistance to first-line EGFR-tyrosine kinase inhibitors (EGFR-TKIs), subsequent treatments typically involve a regimen that includes pemetrexed and platinum. However, the progression-free survival (PFS) achieved with this approach is limited to 4-5 months. There is an urgent need for effective and safe adjuvant therapies. Preliminary research suggests that Chinese herbal medicine (CHM) granules may extend PFS and improve quality of life (QoL), potentially offering a therapeutic strategy for advanced non-small-cell lung cancer (NSCLC). A rigorous, randomized clinical trial is warranted to confirm these findings. The aim of this study is to evaluate the efficacy and safety of CHM granules in combination with chemotherapy for patients with EGFR-mutated advanced lung adenocarcinoma following resistance to first-line EGFR-TKIs. METHOD/
designThis study is a multicenter, double-blind, randomized, placebo-controlled clinical trial in China. A total of 244 patients will be enrolled and randomly assigned to either the treatment group (chemotherapy plus CHM granules, n = 122) or the control group (chemotherapy plus placebo granules, n = 122). The primary outcome measure is PFS, with secondary outcomes including overall survival (OS), objective response rate (ORR), disease control rate (DCR), patient-reported quality of life assessed by the Functional Assessment of Cancer Therapy-Lung (FACT-L) and Lung Cancer Symptom Scale (LCSS), and Traditional Chinese Medicine (TCM) clinical syndrome scores. Adverse events will also be closely monitored. DISCUSSION: The study's findings will provide an evidence-based evaluation of the combination of CHM granules with chemotherapy for treating EGFR-mutated advanced lung adenocarcinoma with resistance to first-line EGFR-TKIs. The results may inform the development of clinical guidelines for adjuvant therapy in this patient population.
trial registrationhttp://www.chictr.org.cn . TRIAL NUMBER: ChiCTR2000029144, Registered on 19 Aug, 2020.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.